HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interactions between tazarotene and ultraviolet light.

Abstract
Tazarotene in combination with phototherapy is being used clinically for the treatment of plaque psoriasis. This study investigates the dose of UVB light required to induce minimal erythema and the dose of UVA light required to induce immediate pigment darkening, with and without pretreatment with tazarotene 0.1% gel. The photostability of tazarotene is also assessed. Pretreatment with tazarotene 0.1% gel 3 times per week for 2 weeks before phototherapy significantly reduced the mean minimal erythema dose (MED) for UVB from 56.25 to 42.50 mJ/cm(2) (P <.01), and significantly reduced the mean UVA exposure required to induce immediate pigment darkening from 20.18 to 18.50 J/cm(2) (P <.05). A thin application of tazarotene gel immediately before phototherapy had no significant effect on the mean MED for UVB, whereas a thick application of the gel increased the MED slightly, from 56.25 to 62.50 mJ/cm(2) (P =.1). Tazarotene remained chemically stable when used in conjunction with UVB or UVA phototherapy. To reduce the patient's potential to burn or tan, we recommend initiating UVB phototherapy at 50% to 75% of the MED when it is used in combination with tazarotene. We also recommend initiating PUVA therapy at slightly lower doses than usual. Lower total doses of UVA or UVB may be needed when patients with psoriasis are treated concomitantly with tazarotene.
AuthorsD Hecker, J Worsley, G Yueh, K Kuroda, M Lebwohl
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 41 Issue 6 Pg. 927-30 (Dec 1999) ISSN: 0190-9622 [Print] United States
PMID10570375 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Dermatologic Agents
  • Gels
  • Nicotinic Acids
  • tazarotene
Topics
  • Adult
  • Chronic Disease
  • Dermatologic Agents (administration & dosage, therapeutic use)
  • Female
  • Gels
  • Humans
  • Male
  • Middle Aged
  • Nicotinic Acids (administration & dosage, therapeutic use)
  • PUVA Therapy
  • Psoriasis (therapy)
  • Treatment Outcome
  • Ultraviolet Therapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: